Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | RARB | P10826 | 5/20 | 0.38 |
| ▸ | RARG | P13631 | 5/20 | 0.38 |
| ▸ | RARA | P10276 | 4/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.38 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.38 |
| ▸ | RXRA | P19793 | 5/20 | 0.37 |
| ▸ | RXRB | P28702 | 4/20 | 0.37 |
| ▸ | RXRG | P48443 | 3/20 | 0.37 |
| ▸ | TDP2 | O95551 | 2/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28842566 | 0.84 | PDK2 (0.46) | HTR7HTR2BRARBRARGRARA | |
| SCHEMBL12050162 | 0.81 | HTT (0.39) | AKR1C3RARBRARGRARACYP26A1 | |
| SCHEMBL12050160 | 0.79 | RXRA (0.42) | AKR1C3RARBRARGRARACYP26A1 | |
| SCHEMBL30571998 | 0.76 | PDK2 (0.55) | HTR7HTR2BRARBRARGRXRA | |
| SCHEMBL4915761 | 0.76 | PDK2 (0.55) | HTR7HTR2BRARBRARGRXRA | |
| SCHEMBL2485238 | 0.75 | AKR1C3 (0.34) | AKR1C3TDP2SRD5A2TTRPDK2 | |
| SCHEMBL2487084 | 0.72 | HTR7 (0.48) | AKR1C3HTR7HTR2BRARBRARG | |
| SCHEMBL21439836 | 0.71 | RARB (0.46) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL29371850 | 0.71 | RARB (0.46) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL2484398 | 0.71 | PTGS1 (0.43) | PDK2PTPRCPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-1923387-B1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1923387-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | HTR2B, HTR7, HTR3B | AKR1C3 2271/4885HTR7 2/4885HTR2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.